Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase III Randomized, Controlled Clinical Trial of Pembrolizumab With or Without Platinum-Based Combination Chemotherapy Versus Chemotherapy in Subjects With Advanced or Metastatic Urothelial Carcinoma
Brief Summary: The purpose of this study is to determine the efficacy and safety of pembrolizumab (pembro, MK-3475) with or without chemotherapy versus chemotherapy alone in participants with advanced or metastatic urothelial carcinoma (bladder cancer).

The primary hypotheses are that pembrolizumab plus chemotherapy is superior to chemotherapy alone with respect to Progression-free Survival (PFS) and Overall Survival (OS) in all participants, and that pembrolizumab alone is superior to chemotherapy alone with respect to OS in all participants and in participants with programmed cell death ligand 1 (PD-L1) positive tumors (Combined Positive Score \[CPS\] ≥10%).


Options:
A: Arm Label: Pembrolizumab + ST Chemotherapy (Pembro Combo); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab, Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine | Arm Label: Pembrolizumab (Pembro); Type: EXPERIMENTAL; Interventions: Biological: Pembrolizumab | Arm Label: ST Chemotherapy (Chemo); Type: ACTIVE_COMPARATOR; Interventions: Drug: Cisplatin, Drug: Carboplatin, Drug: Gemcitabine | Intervention Type: BIOLOGICAL; Name: Pembrolizumab; Assigned to Arm(s): Pembrolizumab (Pembro), Pembrolizumab + ST Chemotherapy (Pembro Combo) | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Pembrolizumab + ST Chemotherapy (Pembro Combo), ST Chemotherapy (Chemo) | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Pembrolizumab + ST Chemotherapy (Pembro Combo), ST Chemotherapy (Chemo) | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Pembrolizumab + ST Chemotherapy (Pembro Combo), ST Chemotherapy (Chemo)
B: Arm Label: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Nivolumab
C: Arm Label: Escalation Cohort (MEDI4736 0.1 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 0.3 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 1 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 3 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Escalation Cohort (MEDI4736 15 mg/kg Q3W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Exploration Durvalumab 20 mg/kg (Q4W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion UM Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion UC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion OC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion STS Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Arm Label: Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W); Type: EXPERIMENTAL; Interventions: Drug: MEDI4736 | Intervention Type: DRUG; Name: MEDI4736; Assigned to Arm(s): Escalation Cohort (MEDI4736 0.1 mg/kg Q2W), Escalation Cohort (MEDI4736 0.3 mg/kg Q2W), Escalation Cohort (MEDI4736 1 mg/kg Q2W), Escalation Cohort (MEDI4736 10 mg/kg Q2W), Escalation Cohort (MEDI4736 15 mg/kg Q3W), Escalation Cohort (MEDI4736 3 mg/kg Q2W), Expansion ACM Cohort (MEDI4736 10 mg/kg Q2W), Expansion GBM Cohort (MEDI4736 10 mg/kg Q2W), Expansion GEC Cohort (MEDI4736 10 mg/kg Q2W), Expansion HCC Total Cohort (MEDI4736 10 mg/kg Q2W), Expansion MSI-high Cancer Cohort (MEDI4736 10 mg/kg Q2W), Expansion NPC Cohort (MEDI4736 10 mg/kg Q2W), Expansion NSCLC Cohort (MEDI4736 10 mg/kg Q2W), Expansion Non-SCCHN Cohort HPV positive (MEDI4736 10 mg/kg Q2W), Expansion OC Cohort (MEDI4736 10 mg/kg Q2W), Expansion PAC Cohort (MEDI4736 10 mg/kg Q2W), Expansion SCCHN Cohort (MEDI4736 10 mg/kg Q2W), Expansion SCLC Cohort (MEDI4736 10 mg/kg Q2W), Expansion STS Cohort (MEDI4736 10 mg/kg Q2W), Expansion TNBC Cohort (MEDI4736 10 mg/kg Q2W), Expansion UC Cohort (MEDI4736 10 mg/kg Q2W), Expansion UM Cohort (MEDI4736 10 mg/kg Q2W), Exploration Durvalumab 20 mg/kg (Q4W)
D: Arm Label: Cohort 2: Participants With Second-line or Beyond Treatments; Type: EXPERIMENTAL; Interventions: Drug: Atezolizumab | Intervention Type: DRUG; Name: Atezolizumab; Assigned to Arm(s): Cohort 2: Participants With Second-line or Beyond Treatments

Answer: A